Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting
H Herrscher, C Robert - Current opinion in oncology, 2020 - journals.lww.com
H Herrscher, C Robert
Current opinion in oncology, 2020•journals.lww.comICI-based immunotherapy radically modified melanoma management and now appear as
the most efficient treatment for patients with metastatic melanoma with characterized by long-
lasting cancer remissions, and a distinct spectrum of immune-related adverse events. Their
efficacy is now also established in the adjuvant setting and they are now actively evaluated
as neoadjuvant treatment with promising early results.
the most efficient treatment for patients with metastatic melanoma with characterized by long-
lasting cancer remissions, and a distinct spectrum of immune-related adverse events. Their
efficacy is now also established in the adjuvant setting and they are now actively evaluated
as neoadjuvant treatment with promising early results.
Summary
ICI-based immunotherapy radically modified melanoma management and now appear as the most efficient treatment for patients with metastatic melanoma with characterized by long-lasting cancer remissions, and a distinct spectrum of immune-related adverse events. Their efficacy is now also established in the adjuvant setting and they are now actively evaluated as neoadjuvant treatment with promising early results.
Lippincott Williams & Wilkins